The U.S. Food and Drug Administration (FDA) and Bellerophon Therapeutics agreed on the design of Bellerophon’s Phase 3…
Articles by Patricia Inácio, PhD
The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However,…
The FPR-1 protein is necessary for the recruitment of immune cells, namely neutrophils and inflammatory macrophages, to the lungs where…
Pliant Therapeutics has raised $100 million in Series C financing that will support the clinical development of PLN-74809,…
Use of INOpulse — inhaled nitric oxide — lessened pulmonary arterial pressure, and the resistance to blood flow in arteries…
In the U.S., 61% of people with idiopathic pulmonary fibrosis (IPF) are prescribed approved anti-fibrotic therapies, namely…
People with idiopathic pulmonary fibrosis have shorter telomeres — the protective caps at the end of chromosomes — but…
The antibiotic azithromycin (AZT), frequently prescribed for fighting bacterial infections, has anti-fibrotic effects and promotes the death of…
Throughout 2019, Pulmonary Fibrosis News provided you daily coverage of breakthrough discoveries, promising therapies, and clinical trials related to …
A model of the human lung constructed with the help of tissue samples from 10 idiopathic pulmonary fibrosis (IPF) patients…